Physician profile
Jesse Duro
NPI 1417720376
$909.27
in general payments reported to CMS, 2019-2025
17 companies · $784 in 2025
The $784 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $125 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.00 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $179.61 | 2024-2025 | Wegovy, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.99 | 2025 | Caplyta |
| Abbvie INC. | $85.75 | 2025 | |
| Viiv Healthcare Company | $66.74 | 2025 | Apretude |
| Indivior INC. | $58.85 | 2025 | Sublocade |
| Sage Therapeutics, LLC | $55.62 | 2025 | Zurzuvae |
| Braeburn INC. | $54.54 | 2025 | Brixadi |
| Bayer Healthcare Pharmaceuticals INC. | $50.31 | 2025 | |
| Exact Sciences Corporation | $41.38 | 2025 | The Cologuard Plus Collection Kit |
| Madrigal Pharmaceuticals | $40.24 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $38.25 | 2025 | Dupixent |
| Averitas Pharma INC. | $31.31 | 2025 | Qutenza |
| Amgen INC. | $25.75 | 2025 | Repatha, Otezla |
| Supernus Pharmaceuticals, INC. | $25.47 | 2025 | Qelbree |
| Hologic Sales and Service, LLC | $24.78 | 2025 | Aptima, Thinprep 2000 Processor |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $24.18 | 2025 | Zepbound |
| Seqirus USA INC | $17.50 | 2025 | Fluad, Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Duro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.